## **Oriahnn (elagolix/estradiol/norethindrone acetate) Prior Authorization Request Form**

**Caterpillar Prescription Drug Benefit** Phone: 877-228-7909 Fax: 800-424-7640

## MEMBER'S LAST NAME: \_\_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME	::	
PHONE NUMBER:	DATE OF BIF	DATE OF BIRTH:	
STREET ADDRESS:			
CITY:	STATE:	ZIP CODE:	
PATIENT INSURANCE ID NUMBER:	· · · · ·		

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

## PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:
---

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THER	APY INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



## Oriahnn (elagolix/estradiol/norethindrone acetate) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
		ICD-10:		
2. LIST DIAGNOSES:		ICD-10:		
□ Other diagnosis:ICD-	10			
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information: Is the patient pre-menopausal?	🗆 No			
Does the patient have a diagnosis of u	iterine fibroids?   Yes  No (please subr	nit a copy of the ultrasound report)		
Is the prescriber an OB/GYN specialist	? 🗆 Yes 🗆 No			
Does the patient have any of the following: persistent or complex ovarian cyst, cancer, current pelvic inflammatory disease, or history of osteoporosis? <ul> <li>Yes</li> <li>No</li> </ul>				
Has patient had prior use of Myfembr	ee(relugolix/estradiol/norethindrone)?	□ Yes □ No		
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
<b>Please note:</b> Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.				
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D.	Verification:	Date:		
<b>CONFIDENTIALITY NOTICE:</b> The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.				
FAX THIS FORM TO: 800-424-7640				
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP – 4201				
P.O. Box 64811				
St. Paul, MN 55164-0811				

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company Revision Date: 08/22/2018

